 Provider News NevadaMay 1, 2025 May 2025 Provider Newsletter Featured Articles Education & Training | Commercial / Medicare Advantage / Medicaid | May 1, 2025 Administrative | Commercial | May 1, 2025
NVBCBS-CDCRCM-081406-25-CPN81360 BackgroundWe previously shared details about an enhancement to the medical claims editing system for pharmaceutical drug procedure codes. This improvement ensures that claims align with FDA‑approved or off‑label indications, based on the list of pharmaceutical compendia defined by CMS. This change aims to promote accuracy in claims and improve reimbursement efficiency. Provider impactBeginning with claims processing on or after June 1, 2025, we will introduce additional drug procedure codes into our system. Codes requiring preapproval or those tied to specific medical policies will not be affected by this update. Note: A drug procedure code will not be approved if the diagnosis reported is not an approved indication. If you would like your claim decision reviewed, follow the claims dispute process outlined in the provider manual. You must include relevant medical record details regarding the drug provided for faster resolution. If you have questions about this notification, contact your contract manager or provider relationship management representative. Thank you for your cooperation and commitment to improving member care. Anthem Blue Cross and Blue Shield Healthcare Solutions is the trade name of Community Care Health Plan of Nevada, Inc. Anthem Blue Cross and Blue Shield is the trade name of Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc., dba HMO Nevada. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NVBCBS-CDCR-078836-25-CPN77148 Annual wellness and well-woman visits are covered with no member cost-sharing when provided by in-network providers for our members with Affordable Care Act (ACA)compliant plans. Individual and small group plan members are encouraged to schedule these visits within the first 90 days of their plan starting or renewing, so your practice may see an increase in requests, especially at the beginning of the second and fourth quarters. Providers can perform the annual wellness or well‑woman visit, even if it has been less than one calendar year since the last wellness visit. We ask that your practice be flexible in accommodating members wanting to schedule their visits earlier than they may have previously. The wellness or well‑woman visit claim will be processed as a preventive care service covered with no member cost share. Please note that this benefit may not apply to all health plans. You should continue to verify eligibility and benefits for all members in Availity Essentials (https://Availity.com) before providing services or receiving member copayments, deductibles, or coinsurance. Anthem Blue Cross and Blue Shield is the trade name of Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc., dba HMO Nevada. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-079025-24-CPN73418 We are excited to announce the opening of West Henderson Hospital, a state‑of‑the‑art facility designed to serve the growing healthcare needs of our community. This innovative hospital features the latest medical technology and comprehensive services, including a full‑service emergency department, advanced inpatient and outpatient surgical suites, diagnostic imaging, and specialized care services. West Henderson Hospital is now accessible to all members across various lines of business, ensuring increased access to care and streamlined patient coordination. We look forward to this new opportunity to support you in providing exceptional healthcare to your patients — our members. Anthem Blue Cross and Blue Shield Healthcare Solutions is the trade name of Community Care Health Plan of Nevada, Inc. Anthem Blue Cross and Blue Shield is the trade name of Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc., dba HMO Nevada. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NVBCBS-CDCRCM-081332-25 Provider Pathways supports the delivery of high‑quality services and value to our members by giving you instant access to premium learning tools and educational resources. The platform’s flexibility empowers you to choose the pace and topics that best suit your needs. What does Provider Pathways offer? - On‑demand training, available 24/7
- Microlearning modules — concise, convenient lessons on a variety of topics
- Specific information essential to our partnership
Recent enhancements: - More topics and content to explore
- A new, user‑friendly menu and navigation experience
- Improved accessibility features:
- Closed captioning
- Voice actors
- Original transcriptions
Please visit the Training Academy to access Provider Pathways and review the modules available. Anthem Blue Cross and Blue Shield Healthcare Solutions is the trade name of Community Care Health Plan of Nevada, Inc. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NVBCBS-CD-079092-25-CPN78159 Manage your prior authorization requests with our digital tools — Availity Essentials and https://anthem.com/provider. These resources simplify requirement determination and request submissions, giving you more time to deliver effective and efficient care to our members. We encourage you to review the instructions below. Determining prior authorization requirementsAvaility Essentials: - Log in to https://Availity.com.
- If you do not already have access, select Get Started to create an account.
- Go to the Payer Spaces tab.
- Select the applicable plan.
- Select Authorization Rules Lookup.
- Enter the required provider information.
- Select Next and enter the required member information.
Note: Final determination of prior authorization requirements is completed upon submission and may differ from search results. Provider website: - Go to https://anthem.com/provider.
- Scroll down and select the applicable state.
- Scroll down to Commercial‑partnered programs and select Access the Commercial Provider site to access the Provider website homepage.
- Under the Resources heading, select Prior Authorization.
- Select the applicable state.
- Select the appropriate link based on the member’s plan.
If the member’s home plan is not with Anthem, scroll to Helpful Links > Select Medical Policy and Prior Authorization for Blue Plans, then follow the prompts to determine the applicable home plan and prior authorization requirements. Submitting prior authorization requestsAvaility Essentials: - Log in to https://Availity.com.
- Select the Patient Registration tab to access Authorizations and Referrals.
- Select Authorization Request.
Note: Transplant prior authorization requests must be submitted by phone, fax, or secure email. Anthem Blue Cross and Blue Shield is the trade name of Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc., dba HMO Nevada. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-081857-25-CPN81558 Anthem is happy to support the announcement of an exciting partnership between Premera Blue Cross, Amazon, and the American College of Lifestyle Medicine (ACLM) offering a free online Lifestyle Medicine & Food as Medicine Essentials Course for the entire provider community. In this comprehensive online course, you will explore the six pillars of lifestyle medicine, emphasizing how food and nutrition can play a critical role in preventing and treating chronic diseases. The course is tailor‑made for healthcare providers looking to enrich their care approach with practical evidence‑based strategies. This course is available until September 14, 2025. Benefits for providers:- Free access: Participate in this valuable training at no cost.
- Earn credits: Completing the course awards, you earn 5.5 CME/CE credits.
- Enhance your practice: Acquire tools to transform care and effectively address chronic disease.
How to enroll:- Visit https://lifestylemedicine.org/essentials.
- Log in or create an ACLM account.
- Enter promo code ESS‑AMZNEDU at checkout to access the course for free.
Contact us Please reach out to Dr. Jon Liu at jonliu@amazon.com with questions regarding the free course. Anthem Blue Cross and Blue Shield is the trade name of Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc., dba HMO Nevada. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-081296-25-CPN80998 Effective on May 2, 2025, Anthem will transition to the following Carelon Medical Benefits Management Clinical Appropriateness Guidelines. This article is to communicate the plan adoption of these guidelines. Existing prior authorization requirements have not changed. In the event a prior authorization requirement for these services will be implemented, a separate notice will be distributed before the addition of any prior authorization requirements. The following guidelines have a publish date of April 1, 2025: - Cardiovascular:
- Ambulatory Cardiac Rhythm Monitoring
- Electrophysiological Studies
- Dialysis Access Evaluations
- Vascular Embolization and Occlusion Procedures
You may access and download a copy of the current and upcoming guidelines here. Please share this notice with other members of your practice and office staff. Anthem Blue Cross and Blue Shield is the trade name of Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc., dba HMO Nevada. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NVBCBS-CR-077988-25-CPN77639 Effective on May 3, 2025, the following Carelon Medical Benefits Management Clinical Appropriateness Guideline updates will be adopted for Anthem. This article is to communicate the plan adoption of these guidelines. Existing prior authorization requirements have not changed. In the event a prior authorization requirement for these services will be implemented, a separate notice will be distributed before the addition of any prior authorization requirements. The following guideline updates have a publish date of 3/23/2025: You may access and download a copy of the current and upcoming guidelines here. Please share this notice with other members of your practice and office staff. Anthem Blue Cross and Blue Shield is the trade name of Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc., dba HMO Nevada. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NVBCBS-CR-080475-25-CPN79949 Effective on May 10, 2025, Anthem will transition to the following Carelon Medical Benefits Management Clinical Appropriateness Guidelines. This article is to communicate the plan adoption of these guidelines. Existing prior authorization requirements have not changed. In the event a prior authorization requirement for these services will be implemented, a separate notice will be distributed before the addition of any prior authorization requirements. The following guidelines have a publish date of April 1, 2025: - Cardiovascular:
- Ambulatory Cardiac Rhythm Monitoring
- Electrophysiological Studies
- Dialysis Access Evaluations
- Vascular Embolization and Occlusion Procedures
You may access and download a copy of the current and upcoming guidelines at https://guidelines.carelonmedicalbenefitsmanagement.com. Please share this notice with other members of your practice and office staff. Anthem Blue Cross and Blue Shield Healthcare Solutions is the trade name of Community Care Health Plan of Nevada, Inc. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NVBCBS-CD-079502-25-CPN78483 This article was updated on June 12, 2025. Effective July 26, 2025, the following Carelon Medical Benefits Management Clinical Appropriateness Guideline updates will be adopted for Anthem. This article is to communicate the plan adoption of these guidelines. Existing preapproval requirements have not changed. In the event of implementation of a preapproval requirement for these services, a separate notice will be distributed before the addition of preapproval requirements. The following guideline updates have a publish date of July 26, 2025: - Genetic Testing:
- Chromosomal Microarray Analysis
- Pharmacogenomic Testing
- Whole Exome Sequencing and Whole Genome Sequencing
- Musculoskeletal:
- Interventional Pain Management
You may access and download a copy of the current and upcoming guidelines here. Please share this notice with other members of your practice and office staff. Anthem Blue Cross and Blue Shield is the trade name of Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc., dba HMO Nevada. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NVBCBS-CR-079681-25-CPN79352, CPN-CR-086307-25-CPN86307 Summary: The Pharmacy and Therapeutics (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem. These policies were developed, revised, or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: - New: newly published criteria
- Revised: addition or removal of medical necessity requirements; new document number
Please share this notice with other members of your practice and office staff. Please note: - The Clinical Criteria listed below apply only to the medical drug benefits contained within the member’s medical plan. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that have been adopted by the health plan only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective Date | Clinical Criteria Number | Clinical Criteria Title | Status | May 7, 2025 | CC-0274 | Bizengri (zenocutuzumab-zbco) | New | May 7, 2025 | CC-0275 | Ziihera (zanidatamab-hrii) | New | May 7, 2025 | CC-0276 | Tryngolza (olezarsen) | New | May 7, 2025 | CC-0072 | Vascular Endothelial Growth Factor (VEGF) Inhibitors | Revised | May 7, 2025 | CC-0185 | Oxlumo (lumasiran) | Revised | May 7, 2025 | CC-0198 | Relizorb (immobilized lipase) cartridge | Revised | May 7, 2025 | CC-0256 | Rivfloza (nedosiran) | Revised | May 7, 2025 | CC-0042 | Monoclonal Antibodies to Interleukin-17 | Revised | May 7, 2025 | CC-0063 | Ustekinumab Agents (Stelara, Selarsdi, Imuldosa, Pyzchiva, Otulfi, Wezlana, Yesintek) | Revised | May 7, 2025 | CC-0058 | Bynfezia Pen, Sandostatin, or Sandostatin LAR (Octreotide) / Octreotide Agents | Revised | May 7, 2025 | CC-0130 | Imfinzi (durvalumab) | Revised | May 7, 2025 | CC-0094 | Pemetrexed | Revised | May 7, 2025 | CC-0078 | Orencia (abatacept) | Revised |
Anthem Blue Cross and Blue Shield Healthcare Solutions is the trade name of Community Care Health Plan of Nevada, Inc. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NVBCBS-CD-079049-25-CPN78054 The Medical Policies, Clinical Utilization Management (UM) Guidelines, and Third-Party Criteria below were developed and/or revised with expanded rationales, medical necessity indications, or criteria. Some may involve changes to policy position statements that might result in services that previously were covered being found to be not medically necessary. Please share this notice with other members of your practice and office staff. To view a guideline, visit the Medical Policies & Clinical UM Guidelines website. Medical PoliciesThe Medical Policy and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to Anthem. These medical policies take effect May 1, 2025. Publish date | Medical Policy number | Medical Policy title | Status | 10/1/2024 | DME.00011 | Electrical Stimulation as a Treatment for Pain and Other Conditions: Surface and Percutaneous Devices | Revised | 10/1/2024 | DME.00052 | Brain Computer Interface Rehabilitation Devices | New | 10/1/2024 | LAB.00026 | Systems Pathology and Multimodal Artificial Intelligence Testing for Cancerous and Precancerous Conditions Previously titled: Systems Pathology and Multimodal Artificial Intelligence Testing for Prostate Cancer | Revised | 10/1/2024 | LAB.00051 | Per- and Polyfluoroalkyl Substances PFAS Testing | New | 10/1/2024 | MED.00150 | Hepzato Kit™ (melphalan hepatic delivery system) | New | 10/1/2024 | SURG.00032 | Patent Foramen Ovale and Left Atrial Appendage Closure Devices Previously titled: Patent Foramen Ovale and Left Atrial Appendage Closure Devices for Stroke Prevention | Revised | 10/1/2024 | TRANS.00023 | Hematopoietic Stem Cell Transplantation for Multiple Myeloma and Other Plasma Cell Dyscrasias | Revised |
Clinical UM GuidelinesThe MPTAC approved the following Clinical UM Guidelines applicable to Anthem. These guidelines were adopted by the medical operations committee for Medicaid members. These guidelines take effect May 1, 2025. Publish date | Clinical UM Guideline number | Clinical UM Guideline title | Status | 10/1/2024 | CG-LAB-33 | Carcinoembryonic Antigen Testing | New | 10/1/2024 | CG-LAB-35 | Cancer Antigen 19-9 Testing | New | 10/1/2024 | CG-MED-39 | Bone Mineral Density Testing Measurement | Revised | 10/1/2024 | CG-SURG-01 | Colonoscopy | Revised | 10/1/2024 | CG-SURG-122 | Lingual Frenotomy for Ankyloglossia-Related Feeding Difficulties | New | 10/1/2024 | CG-SURG-57 | Diagnostic Nasal Endoscopy | Revised |
Anthem Blue Cross and Blue Shield Healthcare Solutions is the trade name of Community Care Health Plan of Nevada, Inc. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NVBCBS-CD-076616-25-CPN76180 The Medical Policies, Clinical Utilization Management (UM) Guidelines, and Third‑Party Criteria below were developed and/or revised with expanded rationales, medical necessity indications, or criteria. Some may involve changes to policy position statements that might result in services that previously were covered being found to be not medically necessary. Please share this notice with other members of your practice and office staff. To view a guideline, visit the Medical Policies & Clinical UM Guidelines website. Medical Policies The medical policy and technology assessment committee (MPTAC) approved the following Medical Policies applicable to Anthem. These medical policies take effect May 25, 2025. Publish date | Medical Policy number | Medical Policy title | Status | 1/30/2025 | DME.00011 | Electrical Stimulation as a Treatment for Pain and Other Conditions: Surface and Percutaneous Devices | Revised | 1/30/2025 | DME.00053 | Home Video-Assisted Robotic Rehabilitation Systems | New | 1/30/2025 | LAB.00026 | Systems Pathology and Multimodal Artificial Intelligence Testing for Cancerous and Precancerous Conditions | Revised | 1/30/2025 | LAB.00037 | Serologic Testing for Biomarkers of Irritable Bowel Syndrome (IBS) | Revised | 1/30/2025 | MED.00151 | Gene Therapy for Aromatic L-Amino Acid Decarboxylase Deficiency | New | 1/30/2025 | MED.00152 | Outpatient Intravenous Insulin Therapy | New | 1/30/2025 | SURG.00165 | Histotripsy | New | 1/30/2025 | TRANS.00029 | Hematopoietic Stem Cell Transplantation for Genetic Diseases and Aplastic Anemias | Revised | 1/30/2025 | TRANS.00033 | Heart Transplantation | Revised |
Clinical UM Guidelines The MPTAC approved the following Clinical UM Guidelines applicable to Anthem. These guidelines were adopted by the medical operations committee for Medicare Advantage members. These guidelines take effect May 25, 2025. Publish date | Clinical UM Guideline number | Clinical UM Guideline title | Status | 1/30/2025 | CG-DME-06 | Compression Devices for Lymphedema | Revised | 1/30/2025 | CG-MED-98 | Parenteral Antibiotics for the Treatment of Lyme Disease | Conversion New | 1/30/2025 | CG-OR-PR-04 | Cranial Remodeling Bands and Helmets (Cranial Orthoses) Previously Titled: Cranial Remodeling Bands and Helmets (Cranial Orthotics) | Revised | 1/30/2025 | CG-RAD-26 | Maternity Ultrasound in the Outpatient Setting Previous category and number: CG-MED-42 | Conversion New | 1/30/2025 | CG-SURG-123 | Autologous Fat Grafting and Injectable Soft Tissue Fillers | Conversion New | 1/30/2025 | CG-SURG-124 | Viscocanalostomy | Conversion New | 1/30/2025 | CG-SURG-125 | Canaloplasty | Conversion New | 1/30/2025 | CG-THER-RAD-07 | Intravascular Coronary and Non-Coronary Brachytherapy Previously Titled: Intravascular Brachytherapy (Coronary and Non-Coronary) | Revised |
Anthem Blue Cross and Blue Shield is the trade name of Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc., dba HMO Nevada. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CR-082359-25-CPN81285 Effective for dates of service on and after August 1, 2025, the following updates will apply to the Carelon Medical Benefits Management Clinical Appropriateness Guidelines. These updates are part of the annual review process to promote clinically appropriate, safe, and affordable healthcare services. Genetic testingChromosomal microarray analysis: - Added neonatal death to the list of indications considered medically necessary.
- Added new section for Optical Genome Mapping (OGM) to clarify as not medically necessary.
Whole Exome Sequencing (WES) and Whole Genome Sequencing: - Clarified and restructured the criteria for improved readability.
- Added Medically Necessary criteria for Prenatal and PostNatal testing
- Added Not Medically Necessary statement for early neonatal death
- Added note that WES may include comparator testing.
Pharmacogenomic testing: - Deleted typo (“one” before “genotyping”) in first sentence
- Added “considered medically necessary for genotyping” to title of Table 1
- Added donanemab‑azbt for neurolytic genotyping for treatment of Alzheimer’s disease
- Added deuruxolitinib for dermatologic genotyping for treatment of alopecia areata
- Added NUDT15 risk allele for hematologic genotyping for thiopurine‑related myelosuppression risk in Asians and Hispanics
- Clarified therapeutic area for Eliglustat as related to hematology rather than pediatrics
Predictive and prognostic polygenic testing: - Updated Description/Scope and Rationale and added References
Musculoskeletal Interventional pain management: - Epidural and intradiscal injection procedures — renamed to include intradiscal injections; clarified requirement for contrast to confirm the needle placement; clarified language addressing when a second injection is indicated; reworded requirements related to advanced imaging.
- Diagnostic selective nerve root block (SNRB) — specified that imaging guidance with contrast to confirm needle position is required unless contraindicated; specified requirement for advanced imaging; clarified that post‑traumatic back pain contraindication applies only when the trauma is acute; added contraindication for cases where imaging studies have shown inadequate epidural space for needle placement at the target level.
- Exclusions:
- Added percutaneous intervertebral disc injection of allogeneic cellular and/or tissue‑based products to the exclusions section for epidural and intradiscal procedures and diagnostic selective root blocks.
- Excluded substances other than corticosteroids (with or without local anesthetic) in therapeutic SI joint injections.
- Intraosseous basivertebral nerve ablation — clarified that this procedure can be done in patients with Type I or Type II Modic changes on magnetic resonance imaging (MRI).
- Sacroiliac joint (SI) injections — clarified that confirmation of needle position must include contrast unless there is a documented allergy:
- Increased volume of injection to 2.5 cc, specified that a repeat SI joint injection is indicated when prior injection provided relief for at least 3 months
- Increased number of repeat therapeutic intraarticular SI joint injections in a 12‑month period from 3 to 4.
- Spinal cord stimulators — clarified that PDN refers to painful diabetic neuropathy:
- Specified nonsurgical low back pain as an exclusion.
As a reminder, ordering and servicing providers may submit preapproval requests to Carelon Medical Benefits Management using the following: - Access the Carelon Medical Benefits Management provider portal directly at www.providerportal.com:
- Online access is available 24/7 to process orders in real‑time and is the fastest and most convenient way to request authorization.
For questions related to guidelines, please email Carelon Medical Benefits Management at MedicalBenefitsManagement.guidelines@Carelon.com. Additionally, you may access and download a copy of the current and upcoming guidelines on the Carelon Medical Benefits Management website by visiting guidelines.carelonmedicalbenefitsmanagement.com. Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Anthem Blue Cross and Blue Shield is the trade name of Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc., dba HMO Nevada. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CRCM-078958-25-CPN78066 Effective June 1, 2025, precertification/prior authorization requirements will change for the following code(s). The medical code(s) listed below will require precertification/prior authorization by Anthem for Nevada Medicaid members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these precertification/prior authorization rules and must be considered first when determining coverage. If the requirements are not met, those services may be deemed ineligible for payment. Providers may appeal online through Availity Essentials or by calling 844‑396‑2330 with additional information that may include medical records. Precertification/prior authorization requirements will be added for the following code(s): Code | Description | L5841 | Addition, endoskeletal knee-shin system, polycentric, pneumatic swing, and stance phase control |
To request precertification/prior authorization, use one of the following methods: Not all precertification/prior authorization requirements are listed here. Detailed precertification/prior authorization requirements are available to providers on https://providers.anthem.com/nv on the Resources tab or for contracted providers by accessing https://Availity.com. Providers may also call Provider Services at 844‑396‑2330 for assistance with precertification/prior authorization requirements. UM AROW A2025M2964 Anthem Blue Cross and Blue Shield Healthcare Solutions is the trade name of Community Care Health Plan of Nevada, Inc. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NVBCBS-CD-078330-25 Effective for dates of service on or after June 1, 2025, the following medication codes will require preapproval. Visit the Clinical Criteria website to search for the specific Clinical Criteria listed below. Clinical Criteria | HCPCS or CPT® code(s) | Drug name | CC-0154 | J0223 | Givlaari (givosiran) |
Please note: Inclusion of a National Drug Code (NDC) on your medical claim is necessary for claims processing. Anthem Blue Cross and Blue Shield Healthcare Solutions is the trade name of Community Care Health Plan of Nevada, Inc. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NVBCBS-CD-081553-25-CPN77844 Effective for dates of service on or after June 1, 2025, the following medication codes will require preapproval. Including a national drug code (NDC) on your medical claim is necessary for claims processing. For more information, click on the Clinical Criteria links in the table below or visit Clinical Criteria and enter the code in the search window. Clinical Criteria | HCPCS or CPT® code(s) | Drug name | CC-0267 | C9399, J3590 | Ebglyss (lebrikizumab-lbkz) | CC-0268 | J9161 | Lymphir (denileukin diftitox-cxdl) | CC-0270 | J9038 | Niktimvo (axatilmab-csfr) | CC-0011 | J2351 | Ocrevus Zunovo (ocrelizumab/hyaluronidase-ocsq) |
Note: Preapproval requests for certain medications may require additional documentation to determine medical necessity. What if I need assistance?If you have any questions, contact your local provider relationship management representative or Provider Services at 844‑396‑2330. Anthem Blue Cross and Blue Shield Healthcare Solutions is the trade name of Community Care Health Plan of Nevada, Inc. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NVBCBS-CD-079709-25-CPN78407 Effective June 1, 2025, the following Medicare Part B medication from the current Clinical Criteria Guidelines will be included in our medical step therapy preapproval review process. Step therapy review will apply upon preapproval initiation in addition to the current medical necessity review (as is current procedure). Step therapy will not apply for members who are actively receiving the medication listed below. Visit our Clinical Criteria page to search for specific criteria. Clinical Criteria | Drug | Status | CC‑0166 | Hercessi (trastuzumab‑strf) | Non‑preferred |
Anthem Blue Cross and Blue Shield is the trade name of Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc., dba HMO Nevada. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CR-077570-25-CPN77133 Effective for dates of service on and after August 1, 2025, the specialty Medicare Part B drug listed in the table below will be included in our preapproval review process. Federal and state law, state contract language, and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over preapproval rules and must be considered first when determining coverage. Claims that do not comply with these new requirements may not be approved. HCPCS code | Medicare Part B drug | Q5136 | Jubbonti; Wyost (denosumab‑bbdz) |
Anthem Blue Cross and Blue Shield is the trade name of Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc., dba HMO Nevada. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CR-077559-25-CPN77132 |